Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder

Multiple Sclerosis

Volumn 23, Issue 9, 2017, Pages 1297-1300

  Yamout, Bassem I ^a   Beaini, Shawkat ^b   Zeineddine, Maya M ^a   Akkawi, Nabil ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Ain Wa Zein Hospital   (Lebanon)

^c Hammoud Hospital   (Lebanon)

Author keywords

aquaporin 4; dimethyl fumarate; Neuromyelitis optica

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOTROPIN; FUMARIC ACID DIMETHYL ESTER; LYMPHOCYTE ANTIBODY; LYMPHOCYTE ANTIGEN; METHYLPREDNISOLONE; PREDNISONE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BLURRED VISION; BRAIN STEM INJURY; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CERVICAL MYELOPATHY; CERVICAL SPINAL CORD; CERVICAL SPINAL CORD INJURY; DIAGNOSTIC ERROR; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; LUMBAR PUNCTURE; LYMPHOCYTE COUNT; MEDULLA OBLONGATA; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; OPTIC NERVE DISEASE; PLASMAPHERESIS; QUADRIPLEGIA; RELAPSE; RESPIRATORY FAILURE; SPINAL CORD DISEASE; TERMINAL DISEASE; VERTIGO; VISUAL EVOKED POTENTIAL; VISUAL IMPAIRMENT; WHITE MATTER LESION; BLINDNESS; CHEMICALLY INDUCED; FATALITY; RECURRENT DISEASE;

ADULT; BLINDNESS; DIAGNOSTIC ERRORS; DIMETHYL FUMARATE; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELITIS; NEUROMYELITIS OPTICA; QUADRIPLEGIA; RECURRENCE;

EID: 85046117279     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458517694086     Document Type: Article

References (11)

1. Wingerchuk D, Banwell B, Bennett J. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.
2. Harmel J, Ringelstein M, Ingwersen J. Interferon−β−related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol 2014; 14: 247–251.
3. Kim SH, Kim W, Li XF. Does interferon-beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012; 18(10): 1480–1483.
4. Shimizu Y, Yokoyama K, Misu T. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 2008; 255: 305–307.
5. Kitley J, Evangelou N, Kuker W. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci 2014; 339: 223–225.
6. Lee DH, Laemmer A, Waschbisch A. Neuromyelitis optica presenting with relapses under treatment with natalizumab: A case report. J Med Case Rep 2014; 8: 155–157.
7. Jacob A, Hutchinson M, Elsone L. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012; 79: 1065–1066.
8. Min JH, Kim B, Lee K., Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18(1): 113–115.
9. Izaki S, Narukawa S, Kubota A. A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment. Clin Neurol 2013; 53: 513–517 (in Japanese).
10. Schilling G, Goelz S, Linker R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006; 145: 101–107.
11. Qian PQ, Cross AH, Naismith RT., Neuromyelitis optica unresponsive to monoclonal antibody therapy. Arch Neurol 2011; 68(9): 1207–1209.